Fu Jian Ping, 10% Owner, subtracted 380,954 shares of NovaBay Pharmaceuticals, Inc. (NBY) from its portfolio at the rate of $3.84 per share valuing $1,462,863 on Jun 11. The insider left behind 5,302,350 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of NovaBay Pharmaceuticals, Inc. (NBY) was $1.96. Currently, the 1st Resistance Point for this stock is $2.13, with a 2nd Resistance Point sitting at $2.31. Meanwhile, this company’s stock has a 1st Support Level at $1.70 and a 2nd Support Level at $1.45. NovaBay Pharmaceuticals, Inc. (NBY) stock has lost -$0.15, or -7.11%, in the past five days. In the last full month, these shares have gained $1.57, or 404.89%. In the past three months, this stock’s price has risen by $0.55, or 39.01%. This year-to-date, NovaBay Pharmaceuticals, Inc. (NBY) shares have gained $1.19, or 154.55%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For NovaBay Pharmaceuticals, Inc. (NBY) stock, 80% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 33% of long-term indicators suggest that this stock is a “ Buy .”
With 18,992 K shares outstanding, this company currently has a market capitalization of $33,236K. NovaBay Pharmaceuticals, Inc. (NBY) generates $12,510 K in annual sales, amounting to annual net income of -$6,540 K. This stock has generated a 1-Year Total Return of -26.04%, a 3-Year Total Return of -22.22%, and a 5-year Total Return of -89.95%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, NovaBay Pharmaceuticals, Inc. (NBY) reported earnings of -$0.28 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.12 per share, representing a -0.16 difference and -143.48% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.07 represented a 0.01 difference from the consensus estimate calling for -$0.08 per share, which was a -15.97% surprise.
In the year-ago quarter, NovaBay Pharmaceuticals, Inc. (NBY) generated per-share earnings of -$0.15. If the analysts are correct about the current quarter’s earnings, the growth will be +666,100.00% .
Turning our focus now to insider trading activity, there have been 0 purchases (0 shares in total) and 4 sale (468,772 shares in total) in the last 3 months. In the last 6 months, there have been 0 insider buys amounting to 0 shares and 4 insider sales amounting to 468,772 shares. In the past full year, 0 insider purchases were made (involving 0 shares) and 4 insider sell-offs equivalent to 468,772 shares.
Moving onto liquidity, NovaBay Pharmaceuticals, Inc. (NBY) has a Current Ratio of 2.24, a Quick Ratio of 2.16 and a Cash Ratio of 0.83.